bs-9432R [Primary Antibody]
RNF27 Polyclonal Antibody
www.biossusa.com
[email protected]
800.501.7654 [DOMESTIC]
+1.781.569.5821 [INTERNATIONAL]
DATASHEET

Host: Rabbit

Target Protein: RNF27

Immunogen Range: 61-160/551


Clonality: Polyclonal

Isotype: IgG

Entrez Gene: 81603

Swiss Prot: Q9BZR9

Source: KLH conjugated synthetic peptide derived from human TRIM8/RNF27

Purification: Purified by Protein A.

Storage Buffer: 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Storage: Shipped at 4C. Store at -20C for one year. Avoid repeated freeze/thaw cycles.

Background:

The tripartite motif (TRIM) family of proteins are characterized by a conserved TRIM domain that includes a coiled-coil region, a B-box type zinc finger, one RING finger and three zinc-binding domains. TRIM8 (tripartite motif containing 8), also known as GERP (glioblastoma-expressed RING finger protein) or RNF27 (RING finger protein 27), is a 551 amino acid protein that is thought to function as an E3 ubiquitin-protein ligase that promotes SOCS-1 proteasomal degradation. As a widely expressed homodimer, TRIM8 localizes to nuclear bodies and contains two B box-type zinc fingers and one RING-type zinc finger. TRIM8 is expressed in lung, heart, brain and skeletal muscle, with low levels detected in intestine, placenta, leukocytes and liver. The gene encoding TRIM8 maps to human chromosome 10q24.32.

Size: 100ul

Concentration: 1ug/ul

Applications: WB(1:300-5000)
IHC-P(1:200-400)
IF(IHC-P)(1:50-200)

Predicted Molecular Weight: 61


Cross Reactive Species: Human
Mouse

Predicted Cross Reactive Species: Rat
Dog
Sheep
Horse
Chicken

For research use only. Not intended for diagnostic or therapeutic use.

VALIDATION IMAGES

Lane 1: HepG2 lysates; Lane 2: Hela lysates probed with GERP Polyclonal Antibody, Unconjugated (bs-9232R) at 1:300 dilution and 4˚C overnight incubation. Followed by conjugated secondary antibody incubation at 1:10000 for 60 min at 37˚C.


Mouse placenta lysates probed with GERP Polyclonal Antibody, Unconjugated (bs-9432R) at 1:300 dilution and 4˚C overnight incubation. Followed by conjugated secondary antibody incubation at 1:10000 for 60 min at 37˚C.